-
公开(公告)号：US20220356180A1
公开(公告)日：2022-11-10
申请号：US17244938
申请日：2021-04-29
Applicant: Bristol-Myers Squibb Company
Inventor： Ryan M. Moslin , David S. Weinstein , Stephen T. Wrobleski , John S. Tokarski , Amit Kumar , Douglas G. Batt , Shuqun Lin , Chunjian Liu , Steven H. Spergel , Yanlei Zhang , Qingjie Liu
IPC: C07D417/14 , C07D403/12 , C07D401/14 , C07D413/14 , C07D401/12 , C07D237/24 , C07D403/14 , C07D413/12 , C07D417/12 , C07B59/00
Abstract: Compounds having the following formula I. or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition.
-
公开(公告)号：US10669272B2
公开(公告)日：2020-06-02
申请号：US16452679
申请日：2019-06-26
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Upender Velaparthi , Louis S. Chupak , Chetan Padmakar Darne , Min Ding , Robert G. Gentles , Yazhong Huang , Manjunatha Narayana Rao Kamble , Scott W. Martin , Raju Mannoori , Ivar M. McDonald , Richard E. Olson , Hasibur Rahaman , Prasada Rao Jalagam , Saumya Roy , Gopikishan Tonukunuru , Sivasudar Velaiah , Jayakumar Sankara Warrier , Xiaofan Zheng , John S. Tokarski , Bireshwar Dasgupta , Kotha Rathnakar Reddy , Thiruvenkadam Raja
IPC: C07D403/04 , C07D487/04 , C07D471/04
Abstract: Disclosed are compounds of Formula (I): or a salt thereof, wherein: R1, R2, R3, R4, R5, and m are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGKα) and diacylglycerol kinase zeta (DGKζ), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.
-
公开(公告)号：US20200109140A1
公开(公告)日：2020-04-09
申请号：US16452679
申请日：2019-06-26
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Upender VELAPARTHI , Louis S. Chupak , Chetan Padmakar Darne , Min Ding , Robert G. Gentles , Yazhong Huang , Manjunatha Narayana Rao Kamble , Scott W. Martin , Raju Mannoori , Ivar M. McDonald , Richard E. Olson , Hasibur Rahaman , Prasada Rao Jalagam , Saumya Roy , Gopikishan Tonukunuru , Sivasudar Velaiah , Jayakumar Sankara Warrier , Xiaofan Zheng , John S. Tokarski , Bireshwar Dasgupta , Kotha Rathnakar Reddy , Thiruvenkadam Raja
IPC: C07D471/04
Abstract: Disclosed are compounds of Formula (I): or a salt thereof, wherein: R1, R2, R3, R4, R5, and m are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGKα) and diacylglycerol kinase zeta (DGKζ), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.
-
4.发明申请ALKYL AMIDE-SUBSTITUTED PYRIMIDINE COMPOUNDS USEFUL IN THE MODULATION OF IL-12, IL-23 AND/OR IFN ALPHA 有权用于调节IL-12，IL-23和/或IFNα的ALKYL酰胺取代的吡咯烷酮化合物公开(公告)号：US20150299139A1
公开(公告)日：2015-10-22
申请号：US14441213
申请日：2013-11-07
Applicant: Bristol-Myers Squibb Company
Inventor： Joseph B. Santella , Ryan M. Moslin , David S. Weinstein , Stephen T. Wrobleski , John S. Tokarski
IPC: C07D239/48
CPC classification number: C07D239/48 , C07D239/95
Abstract: Compounds having the following formula (I): or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα by acting on Tyk-2 to cause signal transduction inhibition.
Abstract translation: 具有下式（I）的化合物或其立体异构体或药学上可接受的盐，其中R 1，R 2，R 3，R 4和R 5如本文所定义，可用于调节IL-12，IL-23和/ 或通过作用于Tyk-2引起信号转导抑制的IFNα。
-
公开(公告)号：US10053454B2
公开(公告)日：2018-08-21
申请号：US14770230
申请日：2014-02-27
Applicant: Bristol-Myers Squibb Company
Inventor： Michael A. Poss , David R. Tortolani , Ashok Vinayak Purandare , John S. Tokarski , Christopher P. Mussari , Muthoni G. Kamau , Dharmpal S. Dodd , Ashvinikumar V. Gavai , Daniel O'Malley , Tram N. Huynh , Wayne Vaccaro , Lalgudi S. Harikrishnan
IPC: C07D413/04 , C07D413/10 , C07D413/14 , C07D417/14 , A61K31/422 , A61K31/427 , A61K31/4439 , A61K31/454 , A61K31/5355 , A61K31/5377 , A61K31/541 , A61K31/553
CPC classification number: C07D413/10 , A61K31/422 , A61K31/427 , A61K31/4439 , A61K31/454 , A61K31/5355 , A61K31/5377 , A61K31/541 , A61K31/553 , C07D413/04 , C07D413/14 , C07D417/14
Abstract: The present invention is directed to carbazole compounds, pharmaceutically acceptable compositions comprising compounds of the invention and methods of using the compositions in the treatment of various disorders.
-
Patent Agency Ranking
公开(公告)号：US20160318928A1
公开(公告)日：2016-11-03
申请号：US15107652
申请日：2014-12-23
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Derek J. Norris , George V. Delucca , Ashvinikumar V. Gavai , Claude A. Quesnelle , Patrice Gill , Daniel O'Malley , Wayne Vaccaro , Francis Y. Lee , Mikkel V. DeBenedetto , Andrew P. Degnan , Haiquan Fang , Matthew D. Hill , Hong Huang , William D. Schmitz , John E. Starrett, JR. , Wen-Ching Han , John S. Tokarski , Sunil Kumar Mandal
IPC: C07D471/04 , A61K31/501 , A61K31/506 , A61K31/437 , A61K31/444
CPC classification number: C07D471/04 , A61K31/437 , A61K31/444 , A61K31/501 , A61K31/506
Abstract: The present invention is directed to tricyclic compounds (I), pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
-
7.发明申请IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN-ALPHA RESPONSES 审中-公开作为IL-12，IL-23和/或IFN-ALPHA反应调节剂的咪达唑啶化合物有用公开(公告)号：US20160304524A1
公开(公告)日：2016-10-20
申请号：US15102991
申请日：2014-12-10
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Chunjian Liu , James Lin , Ryan M. Moslin , David S. Weinstein , John S. Tokarski
IPC: C07D487/04 , C07D498/14
CPC classification number: C07D487/04 , C07D487/14 , C07D498/14
Abstract: Compounds having the following formula (I), or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition.
-
公开(公告)号：US20160108050A1
公开(公告)日：2016-04-21
申请号：US14976476
申请日：2015-12-21
Applicant: Bristol-Myers Squibb Company
Inventor： Ashok Vinayak Purandare , Brian E. Fink , Walter Lewis Johnson , Amy C. Hart , Liqi He , Tram N. Huynh , Jennifer lnghrim , Harold Mastalerz , Xiaopeng Sang , Christine M. Tarby , Honghe Wan , Wayne Vaccaro , Guifen Zhang , Yufen Zhao , Kurt Zimmermann , Yong Zhang , Libing Chen , Bin Chen , John S. Tokarski , Ashvinikumar V. Gavai
IPC: C07D487/04 , C07F9/6561 , C07F7/18 , C07D519/00
CPC classification number: C07D487/04 , A61K31/53 , A61K31/5377 , A61K31/5383 , A61K31/541 , A61K31/55 , A61K31/551 , A61K31/675 , A61K45/06 , C07D471/10 , C07D487/08 , C07D487/10 , C07D487/22 , C07D498/04 , C07D519/00 , C07F7/1804 , C07F9/6521 , C07F9/6561 , C07F9/65616
Abstract: The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The Formula (I) imidazotriazines inhibit protein kinase activity thereby making them useful as anticancer agents.
-
公开(公告)号：US20140256700A1
公开(公告)日：2014-09-11
申请号：US14190477
申请日：2014-02-26
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Michael A. Poss , David R. Tortolani , Dharmpal S. Dodd , Christopher P. Mussari , John S. Tokarski , Ashvinikumar V. Gavai , Yufen Zhao , George V. Delucca , Daniel O'Malley , Derek J. Norris , Patrice Gill , Claude A. Quesnelle , Wen-Ching Han
IPC: A61K31/553 , A61K31/5377 , C07D417/14 , C07D413/14 , A61K31/422 , A61K31/4192 , A61K31/496 , A61K31/427 , A61K31/5355 , A61K31/541 , C07D405/14 , C07D413/04 , A61K31/454
CPC classification number: A61K31/553 , A61K31/4192 , A61K31/422 , A61K31/427 , A61K31/454 , A61K31/496 , A61K31/5355 , A61K31/5377 , A61K31/541 , C07D405/14 , C07D413/04 , C07D413/14 , C07D417/14
Abstract: The present invention is directed to carbazole compounds, pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
Abstract translation: 本发明涉及咔唑化合物，包含本发明化合物的药学上可接受的组合物和使用所述组合物治疗各种疾病的方法。
-
公开(公告)号：US10954238B1
公开(公告)日：2021-03-23
申请号：US16843024
申请日：2020-04-08
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Upender Velaparthi , Louis S. Chupak , Chetan Padmakar Darne , Min Ding , Robert G. Gentles , Yazhong Huang , Manjunatha Narayana Rao Kamble , Scott W. Martin , Raju Mannoori , Ivar M. McDonald , Richard E. Olson , Hasibur Rahaman , Prasada Rao Jalagam , Saumya Roy , Gopikishan Tonukunuru , Sivasudar Velaiah , Jayakumar Sankara Warrier , Xiaofan Zheng , John S. Tokarski , Bireshwar Dasgupta , Kotha Rathnakar Reddy , Thiruvenkadam Raja
IPC: C07D403/04 , C07D487/04 , A61K31/196 , C07D471/04
Abstract: Disclosed are compounds of Formula (I): or a salt thereof, wherein: R1, R2, R3, R4, R5, and m are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGKα) and diacylglycerol kinase zeta (DGKζ), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.
-
-
-
-
-
-
-
-
-
Search Results
42
records
(took 0.057 seconds)
